Dr. Muggia on Targeted Therapies in Ovarian Cancer

Franco M. Muggia, MD
Published Online: Thursday, Nov 14, 2013

Franco M. Muggia, MD, Franco M. Muggia, MD, The Anne Murnick Cogan and David H. Cogan Professor of Oncology, NYU Langone Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.

Muggia says drug development in ovarian cancer has not been easy, resulting in a lack of targeted therapies. Physicians rely on a chemotherapy regimen to treat patients with ovarian cancer that eliminates advanced disease about 80-90% of the time. However, Muggia says, the disease eventually comes back.

Muggia says there is a need to improve treatment for ovarian cancer. BRCA and PARP targets have proven to be good targets to develop further.

Franco M. Muggia, MD, Franco M. Muggia, MD, The Anne Murnick Cogan and David H. Cogan Professor of Oncology, NYU Langone Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.

Muggia says drug development in ovarian cancer has not been easy, resulting in a lack of targeted therapies. Physicians rely on a chemotherapy regimen to treat patients with ovarian cancer that eliminates advanced disease about 80-90% of the time. However, Muggia says, the disease eventually comes back.

Muggia says there is a need to improve treatment for ovarian cancer. BRCA and PARP targets have proven to be good targets to develop further.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Precision Medicine: The Evolving Role of Genomics and Proteomics in Cancer Treatment: Current and Emerging Roles for Molecular Testing Technologies: Real-World Application into PracticeAug 29, 20171.5
Medical Crossfire<sup>®</sup>: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
$emailPop$